A carregar...
γ-Secretase inhibitor–resistant glioblastoma stem cells require RBPJ to propagate
Targeting glioblastoma stem cells with γ-secretase inhibitors (GSIs) disrupts the Notch pathway and has shown some benefit in both pre-clinical models and in patients during phase I/II clinical trials. However, it is largely unknown why some glioblastoma (GBM) does not respond to GSI treatment. In t...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4922718/ https://ncbi.nlm.nih.gov/pubmed/27322058 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI88619 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|